These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3924065)

  • 21. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Vessby B; Lithell H; Ledermann H
    Atherosclerosis; 1982 Jul; 44(1):113-8. PubMed ID: 7115473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.
    Franceschini G; Poli A; Catapano AL; Gatti E; Sirtori M; Gianfranceschi G; Sirtori CR
    Atherosclerosis; 1981; 40(3-4):245-55. PubMed ID: 7332603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment of type III hyperlipoproteinemia with clofibrate.
    Stuyt PM; Demacker PN; Van't Laar A
    Atherosclerosis; 1981; 40(3-4):329-36. PubMed ID: 7332612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
    Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
    Miettinen TA; Huttunen JK; Ehnholm C; Kumlin T; Mattila S; Naukkarinen V
    Atherosclerosis; 1980 Jun; 36(2):249-59. PubMed ID: 6773532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia.
    Boberg J; Boberg M; Gross R; Grundy S; Augustin J; Brown V
    Atherosclerosis; 1977 Aug; 27(4):499-503. PubMed ID: 884004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
    Naruszewicz M; Szostak WB; Cybulska C; Kozłowska M; Chotkowska E
    Atherosclerosis; 1980 Apr; 35(4):383-92. PubMed ID: 7378119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Lang PD
    Atherosclerosis; 1978 Dec; 31(4):429-33. PubMed ID: 215175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients.
    Dujovne CA; Azarnoff DL; Pentikainen P; Manion CV; Hurwitz A
    Am J Med Sci; 1979; 277(3):255-61. PubMed ID: 222145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.
    Goldberg AP; Applebaum-Bowden DM; Bierman EL; Hazzard WR; Haas LB; Sherrard DJ; Brunzell JD; Huttunen JK; Ehnholm C; Nikkila EA
    N Engl J Med; 1979 Nov; 301(20):1073-6. PubMed ID: 226883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia.
    Dean JD; McCarthy S; Betteridge DJ; Whately-Smith C; Powell J; Owens DR
    Diabet Med; 1992; 9(7):611-5. PubMed ID: 1511566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
    Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
    J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.